ZYMEWORKS INC. Increase (Decrease) in Contract with Customer, Liability
ZYMEWORKS INC. (ZYME) reported Increase (Decrease) in Contract with Customer, Liability of -$588.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- ZYMEWORKS INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$248.00K.
- ZYMEWORKS INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$340.00K.
- ZYMEWORKS INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$779.00K.
- ZYMEWORKS INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$614.00K, a 118.42% decline year-over-year.
- ZYMEWORKS INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$23.17M, a 751.76% decline from fiscal 2024.
- ZYMEWORKS INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $3.56M, a 3.89% decline from fiscal 2023.
- ZYMEWORKS INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $3.70M.
- ZYMEWORKS INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$248.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$588.00K 10-Q · filed 2026-08-06 | -$1.37M derived: sum of 3 quarters · filed 2026-08-06 | -$1.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$340.00K 10-Q · filed 2026-05-07 | -$1.12M derived: sum of 2 quarters · filed 2026-05-07 | -$1.73M derived: sum of 3 quarters · filed 2026-05-07 | -$21.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.39M derived: sum of 2 quarters · filed 2026-03-02 | -$21.08M derived: sum of 3 quarters · filed 2026-08-06 | -$23.17M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$614.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$20.30M derived: sum of 2 quarters · filed 2026-08-06 | -$22.39M 10-Q · filed 2025-11-06 | -$23.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$19.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$21.78M 10-Q · filed 2026-08-06 | -$23.38M derived: sum of 3 quarters · filed 2026-08-06 | -$20.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.09M 10-Q · filed 2026-05-07 | -$3.69M derived: sum of 2 quarters · filed 2026-05-07 | -$359.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.72M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.73M derived: sum of 2 quarters · filed 2026-03-02 | $3.81M derived: sum of 3 quarters · filed 2026-03-02 | $3.56M 10-K · filed 2026-03-02 |
| 2024-09-30 | $3.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.41M derived: sum of 2 quarters · filed 2025-11-06 | $5.15M 10-Q · filed 2025-11-06 | $8.76M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.82M 10-Q · filed 2025-08-07 | $5.43M derived: sum of 3 quarters · filed 2026-03-02 | -$9.89M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$259.00K 10-Q · filed 2025-05-08 | $3.35M derived: sum of 2 quarters · filed 2026-03-02 | -$11.97M derived: sum of 3 quarters · filed 2026-03-02 | $3.44M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$11.71M derived: sum of 2 quarters · filed 2026-03-02 | $3.70M derived: sum of 3 quarters · filed 2026-03-02 | $3.70M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$15.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $93.00K derived: sum of 2 quarters · filed 2024-10-31 | $93.00K 10-Q · filed 2024-10-31 | $93.00K derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $15.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $15.41M 10-Q · filed 2024-08-01 | $15.41M derived: sum of 3 quarters · filed 2025-03-05 | $15.41M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 10-K · filed 2025-03-05 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |